Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay

Abstract

// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Maria Schwaederle1, Hatim Husain1, Paul T. Fanta1, David E. Piccioni1, Santosh Kesari1, Richard B. Schwab1, Kimberly C. Banks2, Richard B. Lanman2, AmirAli Talasaz2, Barbara A. Parker1, Razelle Kurzrock1 1Center for Personalized Cancer Therapy and Division of Hematology and Oncology, UCSD Moores Cancer Center, La Jolla, CA, USA 2Guardant Health, Inc., Redwood City, CA, USA Correspondence to: Maria Schwaederle, e-mail: mschwaederle@ucsd.edu Keywords: cancer, liquid biopsy, ctDNA, actionable alteration, personalized therapy Received: September 30, 2015 Accepted: January 23, 2016 Published: February 01, 2016